Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

More than 240 million people worldwide are chronically infected with the hepatitis B virus (HBV) [1 –2]. In the Asia-Pacific region, where it is most prevalent, chronic HBV infection is the leading cause of cirrhosis, liver failure, and hepatocellular carcinoma [2–6]. While currently approved oral nucleos(t)ide analogs effectively suppress viral replication, providing important clinical benefi ts, there are several disadvantages of this therapeutic approach. First, since antiviral therapy is rarely curative, most patients must receive life-long treatment with the attendant cost, cumulative toxicity, and risk of breakthrough through either nonadherence or the emergence of antiviral resista nce.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research

Related Links:

Lay summary: In a large cohort of Caucasians with chronic hepatitis B (CHB) treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) monotherapy, up to 12 years cumulative rates of hepatocellular carcinoma (HCC) did not differ between ETV and TDF in the total group or in any subgroup (with or without cirrhosis, naive or experienced to oral antivirals).
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
ConclusionsIn patients with HBV-related HCC, nucleotide analogues but not nucleoside analogues significantly reduced HCC recurrence and improved overall survival after R0 hepatic resection.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
In Caucasians with chronic hepatitis B, the risk of hepatocellular carcinoma (HCC) after the first 5 years of entecavir or tenofovir therapy depends on age, baseline cirrhosis status and liver stiffness at year 5, which can provide simple and reliable risk scores for HCC prediction and surveillance beyond year 5. In patients with cirrhosis at baseline, liver stiffness
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
This article reviews the mechanisms of carcinogenic HBV by conducting a review of the literature on the efficacy of therapy for reducing the risk of HCC. A few recent articles have suggested that tenofovir offers advantages over entecavir in terms of HCC prevention, but these articles have the inherent limitations of observational data. No other head-to-head randomized trials exist. Further randomized studies would help provide stronger evidence of the association between the type of antiviral agent and the HCC outcomes. Only achieving complete viral eradication from the liver will truly decrease the mortality and incidenc...
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research
Conclusion: AP is still a rare complication after TACE. Etiology is still attributed to the occurrence of shunting and embolization drug reflux. Strategies strengthening the catheter tip that is placed as close to the distal branches of the hepatic artery for the possible careful injection of embolic materials is still the key to avoid post-TACE AP.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
THE GORDON WILSON LECTURE: THE HEPATITIS C VIRUS: FROM HIPPOCRATES TO CURE. Trans Am Clin Climatol Assoc. 2019;130:104-118 Authors: Alter HJ Abstract The modern age of viral hepatitis began in the early 1960s with the serendipitous discovery of the Australia antigen, a protein that was later shown to represent the envelope of the hepatitis B virus leading to its designation as the hepatitis B surface antigen. This was the first marker for any hepatitis virus and became not only a diagnostic assay, but also a mandatory blood donor screening test and the basis for the first generation hepatitis B vaccine...
Source: Transactions of the American Clinical and Climatological Association - Category: General Medicine Tags: Trans Am Clin Climatol Assoc Source Type: research
CONCLUSIONS: The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity. The evidence on the effect of Radix Sophorae flavescentis on the proportion of participants with adverse events considered 'not to be serious' and on the proportion of participants with detectable HBV-DNA is still unclear. We advise caution regarding the results of Radix Sophorae flavescentis showing a reduction in the proportion of people with detectable HBeAg because the trials were at high risk of bias, because it is a non-validated...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
An estimated 248 million individuals live with chronic hepatitis B infection worldwide [1]. Chronic hepatitis B infection (CH-B) has a high risk of progression to cirrhosis and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analogue, is often the drug of choice in nucleoside-na ïve patients with CH-B because of its low rate of viral resistance. Resistance to entecavir therapy in nucleoside-naïve patients is approximately 1 percent after five years of treatment [2]. The efficacy and safety of entecavir has been well-studied in different patient populations with CH-B.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
More News: Antiviral Therapy | Cancer & Oncology | Carcinoma | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis B | Hepatitis Vaccine | Hepatocellular Carcinoma | Liver | Liver Cancer | Oral Cancer | Study | Toxicology | Urology & Nephrology | Vaccines